Levosimendan vs enoximone
All‐cause short‐term mortality: 30 days · adults with cardiogenic shock
It is very uncertain whether levosimendan changes all‐cause short‐term mortality: 30 days compared with enoximone (very low certainty).
1 finding from 1 review
- Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes onlyRR 0.5 [0.22, 1.14]1 study · 32 participantsVery low